Pharmaceutical compounds, methods and ingredients are provided to reduce the number or activity of TAU RNM in a cell or animal and, in some cases, the TAU protein in a cell or animal. Compounds, methods and ingredients of these drugs help to improve the symptoms of at least one neurodegenerative disease. These five symptoms include loss of memory, loss of motor function and increased content and/or volume of nerve fibers. These neurodegenerative diseases include Tauppates, Alzheimer's disease, and Forehead Mental Disorder (FTD).FTDP-17, progressive hypervelocity paralysis (PSP),Chronic traumatic encephalopathy (CTE)Cortical scurvy (CBD)Epilepsia and Dravet syndrome.Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of tau mRNA in a cell or animal, and in certain instances reduce the amount of tau protein a cell or animal. Such compounds, methods, and pharmaceutical compositions are used to ameliorate at least one symptom of a neurogradiative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and/or volume of neur fiber illary inclusions. Such neurogradiative disease s include taopathies, alzheimer's disease, fronto-temporal dementia (FTD),FTDP-17, Progressive Supranclear Palsy (PSP),Chronic Traumatic Cenphalopathy (CTE)Corticobasal Ganglionic Degradation (CBD),Epilepsy, and Dravet's Syndrome.Se proporcionan compuestos, métodos y composiciones farmacéuticas para reducir la cantidad o la actividad del ARNm de Tau en una célula o animal, y en determinados casos para reducir la cantidad de proteína Tau en una célula o animal. Tales compuestos, métodos y composiciones farmacéuticas son útiles para mejorar al menos un síntoma de una enfermedad neurodegenerativa. Dichos 5 síntomas incluyen pérdida de memoria, pérdida de la función motora y aumento en la cantidad y/o el volumen de las inclusiones neurofibrilares. Dichas enfermedades neurodegenerativos incluyen taupatías, enferme
